Does higher SHBG lower free testosterone bioavailability?

Sex hormone-binding globulin (SHBG) is a primary regulatory glycoprotein that dictates the tissue-level availability of circulating androgens. In women, particularly during the postmenopausal transition, changes in SHBG concentrations significantly alter active hormone levels.

Physiological dynamics and binding affinity

• Androgen sequestration: Approximately 65% of circulating testosterone is bound to SHBG with high affinity under normal physiological conditions. The remainder is weakly bound to albumin or exists as a tiny, unbound free fraction.
• Reduction of active hormone: When SHBG levels rise, a larger physical fraction of circulating testosterone is sequestered. According to the Vermeulen equation, higher SHBG concentrations directly drive down the calculated free, biologically active testosterone fraction, even when total testosterone levels remain unchanged.

Metabolic and hormonal modulators

• Estrogen-induced elevation: Oral estrogen therapy significantly stimulates hepatic synthesis of SHBG. This elevation further sequesters circulating androgens, reducing free testosterone bioavailability in postmenopausal women.
• Metabolic suppression: Conversely, insulin resistance, obesity, and increased visceral adiposity suppress hepatic SHBG production. This downregulation decreases the bound fraction, leading to a higher proportion of free, biologically active testosterone.

Bottom line

• Higher SHBG concentrations directly reduce free testosterone bioavailability by sequestering a larger fraction of the circulating hormone. Consequently, total testosterone measurements alone can be misleading, and clinical evaluations must account for SHBG levels—particularly in the context of oral estrogen therapy or metabolic conditions.